<DOC>
	<DOCNO>NCT00836472</DOCNO>
	<brief_summary>The objective study compare rate extent absorption Glyburide/Metformin 5 mg/500 mg film-coated tablet ( test ) versus GlucovanceÂ® ( reference ) administer 1 x 5 mg/500 mg film-coated tablet fast condition .</brief_summary>
	<brief_title>Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets , Fasting</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glyburide</mesh_term>
	<criteria>Subjects females and/or male , nonsmoker , 18 year age old . Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HIV screen . Subjects BMI le equal 30.0 . History significant alcohol abuse within six month screen visit indication regular use fourteen unit alcohol per week ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . History allergic reaction glyburide metformin relate drug ( e.g . chlorpropamide , gliclazide , tolbutamide , furosemide , sulfamethoxazole , sulfadiazine sulfisoxazole ) . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . History presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease condition know interfere absorption , distribution , metabolism excretion drug . Any history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric metabolic disease . Use prescription medication within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication except topical product without systemic absorption . Positive alcohol breath test screening . subject use tobacco form within 90 day precede study drug administration . Intolerance venipuncture . Any food allergy , intolerance , restriction , special diet , opinion medical subinvestigator , contraindicate subject 's participation study . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : less 300 mL whole blood within 30 day ; 300 mL 500 mL whole blood within 45 day ; 500 mL whole blood within 56 day . Subjects clinically significant history tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . History metabolic acidosis , congestive heart failure myocardial infarction . Breastfeeding subject . Positive urine pregnancy test screening ( performed female ) . Female subject childbearing potential unprotected sexual intercourse nonsteril male partner ( i.e . male sterilized vasectomy least 6 month ) within 14 day prior study drug administration . The acceptable method contraception : 1 . Condom + spermicide 2 . Diaphragm + spermicide 3 . Intrauterine contraceptive device ( place least 4 week prior study drug administration )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>